Saturday, 23 March 2019
There are currently no vacancies
The Medicines Control Authority of Zimbabwe (MCAZ) Regional Centre of Regulatory Excellence
(ReCORE) in partnership with the European and Developing Countries Clinical Trials Partnership
(EDCTP) is offering a 2-year fellowship in regulatory science to 8 – 10 assessors working in African medicines regulatory authorities (MRA). Fellows will be admitted in two groups, the first in 2019 and the second group in 2020. The MCAZ is a leading regulator on the African continent and has trained regulators from all over the continent for many years.
The fellowship will involve completion of short courses through block release training at the MCAZ / University of Zimbabwe (UZ), completion of the summer course and winter mini-conference at the Utrecht-WHO Collaborating Centre for Pharmaceutical Policy and Regulation in the Netherlands, practical work assignments, case studies, specific hours of practice (dossier assessments) over the fellowship period and a capstone project. The capstone project should be in the area of specialisation selected by the fellow and address a specific problem, issue or research question in regulatory science. Funding will be provided for 8 fellows and 2 additional fellows will be accepted provided they can fund themselves. The approximate cost of the fellowship is US$28 950 for the entire fellowship period.
In this issue:
MCAZ turns 20 years
Basics of reporting Side Effects of medicines Electronic Adverse Drug Reaction Reporting
For more information Please click here to download the Newsletter
The Quality Policy of the Medicines Control Authority of Zimbabwe (MCAZ) is to ensure the provision of accurate and timeous services, continuously meet requirements of our customers and guarantee patient safety as stated in the Medicines and Allied Substances Control Act (Chapter 15:03). This enables the Authority to be an effective medicines regulator in Zimbabwe and a leading regulatory authority in the world. MCAZ is committed to protecting the public and animal health by ensuring that accessible medicines, allied substances and medical devices are safe, effective and of good quality. This is achieved by carrying out activities in accordance with the relevant procedures and specifications.
Click here to view Quality Policy Statement
Increased Reporting from the Targeted Spontaneous Reporting (TSR) Programme
Click here to download Drug Information Bulletin
